AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). AzurRx is pursuing parallel clinical pathways for MS1819 – a Phase 2b monotherapy clinical trial and a Phase 2 combination therapy trial.
The Company is launching two new clinical programs in 2021 using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-1022, for COVID-19 gastrointestinal infections, currently in Phase 2 clinical trials, and FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients, with anticipated Phase 1b/2a trial initiation in Q2 2021.
The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California.